APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oncology Based Preclinical CRO

Preclinical research refers to before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. A Preclinical CRO, or preclinical contract research organization, provides the experience, knowledge, and skill required to take a pharmaceutical product or medical device from the drawing board to distribution. This journey entails a plethora of activities that involve scientists, medical personnel, administrators, governmental and industry liaisons, marketing experts, and a host of other technical and creative individuals. Rarely is this unique combination of credentials and craft already present within a sponsoring organization. The CRO industry emerged to fill this much-needed role, to provide the expertise required to bring a pharmaceutical product or medical device into the marketplace as quickly and smoothly as possible.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Preclinical research refers to before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. A Preclinical CRO, or preclinical contract research organization, provides the experience, knowledge, and skill required to take a pharmaceutical product or medical device from the drawing board to distribution. This journey entails a plethora of activities that involve scientists, medical personnel, administrators, governmental and industry liaisons, marketing experts, and a host of other technical and creative individuals. Rarely is this unique combination of credentials and craft already present within a sponsoring organization. The CRO industry emerged to fill this much-needed role, to provide the expertise required to bring a pharmaceutical product or medical device into the marketplace as quickly and smoothly as possible.

Selected research

Market Analysis & Forecast

Global Oncology Based Preclinical CRO Market Analysis and Forecast 2026-2032

Report ID 173895030227 December 2025195 pages

Choose your research edition.

Industry ResearchOncology Based Preclinical CRO Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Based Preclinical CRO Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Oncology Based Preclinical CRO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Based Preclinical CRO Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Based Preclinical CRO Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

Preclinical research refers to before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. A Preclinical CRO, or preclinical contract research organization, provides the experience, knowledge, and skill required to take a pharmaceutical product or medical device from the drawing board to distribution. This journey entails a plethora of activities that involve scientists, medical personnel, administrators, governmental and industry liaisons, marketing experts, and a host of other technical and creative individuals. Rarely is this unique combination of credentials and craft already present within a sponsoring organization. The CRO industry emerged to fill this much-needed role, to provide the expertise required to bring a pharmaceutical product or medical device into the marketplace as quickly and smoothly as possible.

The industry's leading producers are Crown Bioscience, Charles River and ICON, with revenues of 18.32 percent, 13.86 percent and 9.13 percent in 2019.

Report Includes

Read the full market overview

This report presents an overview of global market for Oncology Based Preclinical CRO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oncology Based Preclinical CRO, also provides the revenue of main regions and countries. Of the upcoming market potential for Oncology Based Preclinical CRO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oncology Based Preclinical CRO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oncology Based Preclinical CRO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Oncology Based Preclinical CRO revenue, projected growth trends, production technology, application and end-user industry.

Oncology Based Preclinical CRO Segment by Company

Crown Bioscience

Charles River

ICON

Eurofins Scientific

Taconic Biosciences

Covance

EVOTEC

The Jackson Laboratory

MI Bioresearch

Champion Oncology

Wuxi AppTec.

Xentech

Living Tumor Laboratory

Oncology Based Preclinical CRO Segment by Type

Blood Cancer

Solid Tumors

Others

Oncology Based Preclinical CRO Segment by Application

In Vitro

In Vivo

Oncology Based Preclinical CRO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Based Preclinical CRO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Based Preclinical CRO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Based Preclinical CRO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Oncology Based Preclinical CRO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Oncology Based Preclinical CRO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Based Preclinical CRO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oncology Based Preclinical CRO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Blood Cancer Major Player Table 3. Solid Tumors Major Player Table 4. Others Major Player Table 5. Global Oncology Based Preclinical CRO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. In Vitro Major Player Table 7. In Vivo Major Player Table 8. Oncology Based Preclinical CRO Industry Trends Table 9. Oncology Based Preclinical CRO Industry Drivers Table 10. Oncology Based Preclinical CRO Industry Opportunities and Challenges Table 11. Oncology Based Preclinical CRO Industry Restraints Table 12. Global Oncology Based Preclinical CRO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Oncology Based Preclinical CRO Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Oncology Based Preclinical CRO Market Share by Region (2021-2026) Table 15. Global Oncology Based Preclinical CRO Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Oncology Based Preclinical CRO Market Share by Region (2027-2032) Table 17. Global Oncology Based Preclinical CRO Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Oncology Based Preclinical CRO Revenue Market Share by Players (2021-2026) Table 19. Global Oncology Based Preclinical CRO Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Oncology Based Preclinical CRO Key Players Headquarters & Area Served Table 21. Global Oncology Based Preclinical CRO Players, Product Type & Application Table 22. Global Oncology Based Preclinical CRO Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Oncology Based Preclinical CRO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Oncology Based Preclinical CRO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Oncology Based Preclinical CRO Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Oncology Based Preclinical CRO Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Oncology Based Preclinical CRO Revenue Market Share by Type (2021-2026) Table 29. Global Oncology Based Preclinical CRO Revenue Market Share by Type (2027-2032) Table 30. Global Oncology Based Preclinical CRO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Oncology Based Preclinical CRO Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Oncology Based Preclinical CRO Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Oncology Based Preclinical CRO Revenue Market Share by Application (2021-2026) Table 34. Global Oncology Based Preclinical CRO Revenue Market Share by Application (2027-2032) Table 35. Crown Bioscience Company Information Table 36. Crown Bioscience Business Overview Table 37. Crown Bioscience Oncology Based Preclinical CRO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Crown Bioscience Oncology Based Preclinical CRO Product Portfolio Table 39. Crown Bioscience Recent Development Table 40. Charles River Company Information Table 41. Charles River Business Overview Table 42. Charles River Oncology Based Preclinical CRO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Charles River Oncology Based Preclinical CRO Product Portfolio Table 44. Charles River Recent Development Table 45. ICON Company Information Table 46. ICON Business Overview Table 47. ICON Oncology Based Preclinical CRO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. ICON Oncology Based Preclinical CRO Product Portfolio Table 49. ICON Recent Development Table 50. Eurofins Scientific Company Information Table 51. Eurofins Scientific Business Overview Table 52. Eurofins Scientific Oncology Based Preclinical CRO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Eurofins Scientific Oncology Based Preclinical CRO Product Portfolio Table 54. Eurofins Scientific Recent Development Table 55. Taconic Biosciences Company Information Table 56. Taconic Biosciences Business Overview Table 57. Taconic Biosciences Oncology Based Preclinical CRO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Taconic Biosciences Oncology Based Preclinical CRO Product Portfolio Table 59. Taconic Biosciences Recent Development Table 60. Covance Company Information Table 61. Covance Business Overview Table 62. Covance Oncology Based Preclinical CRO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Covance Oncology Based Preclinical CRO Product Portfolio Table 64. Covance Recent Development Table 65. EVOTEC Company Information Table 66. EVOTEC Business Overview Table 67. EVOTEC Oncology Based Preclinical CRO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. EVOTEC Oncology Based Preclinical CRO Product Portfolio Table 69. EVOTEC Recent Development Table 70. The Jackson Laboratory Company Information Table 71. The Jackson Laboratory Business Overview Table 72. The Jackson Laboratory Oncology Based Preclinical CRO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. The Jackson Laboratory Oncology Based Preclinical CRO Product Portfolio Table 74. The Jackson Laboratory Recent Development Table 75. MI Bioresearch Company Information Table 76. MI Bioresearch Business Overview Table 77. MI Bioresearch Oncology Based Preclinical CRO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. MI Bioresearch Oncology Based Preclinical CRO Product Portfolio Table 79. MI Bioresearch Recent Development Table 80. Champion Oncology Company Information Table 81. Champion Oncology Business Overview Table 82. Champion Oncology Oncology Based Preclinical CRO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Champion Oncology Oncology Based Preclinical CRO Product Portfolio Table 84. Champion Oncology Recent Development Table 85. Wuxi AppTec. Company Information Table 86. Wuxi AppTec. Business Overview Table 87. Wuxi AppTec. Oncology Based Preclinical CRO Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 88. Wuxi AppTec. Oncology Based Preclinical CRO Product Portfolio Table 89. Wuxi AppTec. Recent Development Table 90. Xentech Company Information Table 91. Xentech Business Overview Table 92. Xentech Oncology Based Preclinical CRO Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 93. Xentech Oncology Based Preclinical CRO Product Portfolio Table 94. Xentech Recent Development Table 95. Living Tumor Laboratory Company Information Table 96. Living Tumor Laboratory Business Overview Table 97. Living Tumor Laboratory Oncology Based Preclinical CRO Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 98. Living Tumor Laboratory Oncology Based Preclinical CRO Product Portfolio Table 99. Living Tumor Laboratory Recent Development Table 100. North America Oncology Based Preclinical CRO Revenue by Type (2021-2026) & (US$ Million) Table 101. North America Oncology Based Preclinical CRO Revenue by Type (2027-2032) & (US$ Million) Table 102. North America Oncology Based Preclinical CRO Revenue by Application (2021-2026) & (US$ Million) Table 103. North America Oncology Based Preclinical CRO Revenue by Application (2027-2032) & (US$ Million) Table 104. North America Oncology Based Preclinical CRO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. North America Oncology Based Preclinical CRO Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Oncology Based Preclinical CRO Revenue by Country (US$ Million) & (2027-2032) Table 107. Europe Oncology Based Preclinical CRO Revenue by Type (2021-2026) & (US$ Million) Table 108. Europe Oncology Based Preclinical CRO Revenue by Type (2027-2032) & (US$ Million) Table 109. Europe Oncology Based Preclinical CRO Revenue by Application (2021-2026) & (US$ Million) Table 110. Europe Oncology Based Preclinical CRO Revenue by Application (2027-2032) & (US$ Million) Table 111. Europe Oncology Based Preclinical CRO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. Europe Oncology Based Preclinical CRO Revenue by Country (2021-2026) & (US$ Million) Table 113. Europe Oncology Based Preclinical CRO Revenue by Country (US$ Million) & (2027-2032) Table 114. China Oncology Based Preclinical CRO Revenue by Type (2021-2026) & (US$ Million) Table 115. China Oncology Based Preclinical CRO Revenue by Type (2027-2032) & (US$ Million) Table 116. China Oncology Based Preclinical CRO Revenue by Application (2021-2026) & (US$ Million) Table 117. China Oncology Based Preclinical CRO Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Oncology Based Preclinical CRO Revenue by Type (2021-2026) & (US$ Million) Table 119. Asia Oncology Based Preclinical CRO Revenue by Type (2027-2032) & (US$ Million) Table 120. Asia Oncology Based Preclinical CRO Revenue by Application (2021-2026) & (US$ Million) Table 121. Asia Oncology Based Preclinical CRO Revenue by Application (2027-2032) & (US$ Million) Table 122. Asia Oncology Based Preclinical CRO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 123. Asia Oncology Based Preclinical CRO Revenue by Region (US$ Million) & (2021-2026) Table 124. Asia Oncology Based Preclinical CRO Revenue by Region (US$ Million) & (2027-2032) Table 125. SAMEA Oncology Based Preclinical CRO Revenue by Type (2021-2026) & (US$ Million) Table 126. SAMEA Oncology Based Preclinical CRO Revenue by Type (2027-2032) & (US$ Million) Table 127. SAMEA Oncology Based Preclinical CRO Revenue by Application (2021-2026) & (US$ Million) Table 128. SAMEA Oncology Based Preclinical CRO Revenue by Application (2027-2032) & (US$ Million) Table 129. SAMEA Oncology Based Preclinical CRO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 130. SAMEA Oncology Based Preclinical CRO Revenue by Country (2021-2026) & (US$ Million) Table 131. SAMEA Oncology Based Preclinical CRO Revenue by Country (US$ Million) & (2027-2032) Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Oncology Based Preclinical CRO Image Figure 2. Global Oncology Based Preclinical CRO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology Based Preclinical CRO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Blood Cancer Image Figure 5. Solid Tumors Image Figure 6. Others Image Figure 7. Global Oncology Based Preclinical CRO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Oncology Based Preclinical CRO Market Size Share 2021 VS 2025 VS 2032 Figure 9. In Vitro Image Figure 10. In Vivo Image Figure 11. Global Oncology Based Preclinical CRO Market Size (US$ Million) & (2021-2032) Figure 12. Global Oncology Based Preclinical CRO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Oncology Based Preclinical CRO Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Oncology Based Preclinical CRO Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Oncology Based Preclinical CRO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Oncology Based Preclinical CRO Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Oncology Based Preclinical CRO Revenue Market Share by Type (2021-2032) Figure 19. Global Oncology Based Preclinical CRO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Oncology Based Preclinical CRO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Oncology Based Preclinical CRO Revenue Market Share by Application (2021-2032) Figure 22. North America Oncology Based Preclinical CRO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Oncology Based Preclinical CRO Revenue Share by Type (2021-2032) Figure 24. North America Oncology Based Preclinical CRO Revenue Share by Application (2021-2032) Figure 25. North America Oncology Based Preclinical CRO Revenue Share by Country (2021-2032) Figure 26. United States Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Oncology Based Preclinical CRO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Oncology Based Preclinical CRO Revenue Share by Type (2021-2032) Figure 31. Europe Oncology Based Preclinical CRO Revenue Share by Application (2021-2032) Figure 32. Europe Oncology Based Preclinical CRO Revenue Share by Country (2021-2032) Figure 33. Germany Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Oncology Based Preclinical CRO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Oncology Based Preclinical CRO Revenue Share by Type (2021-2032) Figure 43. China Oncology Based Preclinical CRO Revenue Share by Application (2021-2032) Figure 44. Asia Oncology Based Preclinical CRO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Oncology Based Preclinical CRO Revenue Share by Type (2021-2032) Figure 46. Asia Oncology Based Preclinical CRO Revenue Share by Application (2021-2032) Figure 47. Asia Oncology Based Preclinical CRO Revenue Share by Region (2021-2032) Figure 48. Japan Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Oncology Based Preclinical CRO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Oncology Based Preclinical CRO Revenue Share by Type (2021-2032) Figure 56. SAMEA Oncology Based Preclinical CRO Revenue Share by Application (2021-2032) Figure 57. SAMEA Oncology Based Preclinical CRO Revenue Share by Country (2021-2032) Figure 58. Brazil Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Oncology Based Preclinical CRO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Blood Cancer
  • Solid Tumors
  • Others
Applications
  • In Vitro
  • In Vivo
Companies covered
  • Crown Bioscience
  • Charles River
  • ICON
  • Eurofins Scientific
  • Taconic Biosciences
  • Covance
  • EVOTEC
  • The Jackson Laboratory
  • MI Bioresearch
  • Champion Oncology
  • Wuxi AppTec.
  • Xentech
  • Living Tumor Laboratory

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oncology Based Preclinical CRO Market by Type
  3. 1.2.1 Global Oncology Based Preclinical CRO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Blood Cancer
  5. 1.2.3 Solid Tumors
  6. 1.2.4 Others
  7. 1.3 Oncology Based Preclinical CRO Market by Application
  8. 1.3.1 Global Oncology Based Preclinical CRO Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 In Vitro
  10. 1.3.3 In Vivo
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Oncology Based Preclinical CRO Market Dynamics
  1. 2.1 Oncology Based Preclinical CRO Industry Trends
  2. 2.2 Oncology Based Preclinical CRO Industry Drivers
  3. 2.3 Oncology Based Preclinical CRO Industry Opportunities and Challenges
  4. 2.4 Oncology Based Preclinical CRO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Oncology Based Preclinical CRO Market Perspective (2021-2032)
  2. 3.2 Global Oncology Based Preclinical CRO Growth Trends by Region
  3. 3.2.1 Global Oncology Based Preclinical CRO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oncology Based Preclinical CRO Market Size by Region (2021-2026)
  5. 3.2.3 Global Oncology Based Preclinical CRO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Oncology Based Preclinical CRO Revenue by Players
  2. 4.1.1 Global Oncology Based Preclinical CRO Revenue by Players (2021-2026)
  3. 4.1.2 Global Oncology Based Preclinical CRO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Oncology Based Preclinical CRO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oncology Based Preclinical CRO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Oncology Based Preclinical CRO Key Players Headquarters & Area Served
  7. 4.4 Global Oncology Based Preclinical CRO Players, Product Type & Application
  8. 4.5 Global Oncology Based Preclinical CRO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Oncology Based Preclinical CRO Market CR5 and HHI
  11. 4.6.3 2025 Oncology Based Preclinical CRO Tier 1, Tier 2, and Tier 3
5 Oncology Based Preclinical CRO Market Size by Type
  1. 5.1 Global Oncology Based Preclinical CRO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Oncology Based Preclinical CRO Revenue by Type (2021-2032)
  3. 5.3 Global Oncology Based Preclinical CRO Revenue Market Share by Type (2021-2032)
6 Oncology Based Preclinical CRO Market Size by Application
  1. 6.1 Global Oncology Based Preclinical CRO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Oncology Based Preclinical CRO Revenue by Application (2021-2032)
  3. 6.3 Global Oncology Based Preclinical CRO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Crown Bioscience
  2. 7.1.1 Crown Bioscience Company Information
  3. 7.1.2 Crown Bioscience Business Overview
  4. 7.1.3 Crown Bioscience Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Crown Bioscience Oncology Based Preclinical CRO Product Portfolio
  6. 7.1.5 Crown Bioscience Recent Developments
  7. 7.2 Charles River
  8. 7.2.1 Charles River Company Information
  9. 7.2.2 Charles River Business Overview
  10. 7.2.3 Charles River Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Charles River Oncology Based Preclinical CRO Product Portfolio
  12. 7.2.5 Charles River Recent Developments
  13. 7.3 ICON
  14. 7.3.1 ICON Company Information
  15. 7.3.2 ICON Business Overview
  16. 7.3.3 ICON Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 ICON Oncology Based Preclinical CRO Product Portfolio
  18. 7.3.5 ICON Recent Developments
  19. 7.4 Eurofins Scientific
  20. 7.4.1 Eurofins Scientific Company Information
  21. 7.4.2 Eurofins Scientific Business Overview
  22. 7.4.3 Eurofins Scientific Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Eurofins Scientific Oncology Based Preclinical CRO Product Portfolio
  24. 7.4.5 Eurofins Scientific Recent Developments
  25. 7.5 Taconic Biosciences
  26. 7.5.1 Taconic Biosciences Company Information
  27. 7.5.2 Taconic Biosciences Business Overview
  28. 7.5.3 Taconic Biosciences Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Taconic Biosciences Oncology Based Preclinical CRO Product Portfolio
  30. 7.5.5 Taconic Biosciences Recent Developments
  31. 7.6 Covance
  32. 7.6.1 Covance Company Information
  33. 7.6.2 Covance Business Overview
  34. 7.6.3 Covance Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Covance Oncology Based Preclinical CRO Product Portfolio
  36. 7.6.5 Covance Recent Developments
  37. 7.7 EVOTEC
  38. 7.7.1 EVOTEC Company Information
  39. 7.7.2 EVOTEC Business Overview
  40. 7.7.3 EVOTEC Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 EVOTEC Oncology Based Preclinical CRO Product Portfolio
  42. 7.7.5 EVOTEC Recent Developments
  43. 7.8 The Jackson Laboratory
  44. 7.8.1 The Jackson Laboratory Company Information
  45. 7.8.2 The Jackson Laboratory Business Overview
  46. 7.8.3 The Jackson Laboratory Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 The Jackson Laboratory Oncology Based Preclinical CRO Product Portfolio
  48. 7.8.5 The Jackson Laboratory Recent Developments
  49. 7.9 MI Bioresearch
  50. 7.9.1 MI Bioresearch Company Information
  51. 7.9.2 MI Bioresearch Business Overview
  52. 7.9.3 MI Bioresearch Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 MI Bioresearch Oncology Based Preclinical CRO Product Portfolio
  54. 7.9.5 MI Bioresearch Recent Developments
  55. 7.10 Champion Oncology
  56. 7.10.1 Champion Oncology Company Information
  57. 7.10.2 Champion Oncology Business Overview
  58. 7.10.3 Champion Oncology Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Champion Oncology Oncology Based Preclinical CRO Product Portfolio
  60. 7.10.5 Champion Oncology Recent Developments
  61. 7.11 Wuxi AppTec.
  62. 7.11.1 Wuxi AppTec. Company Information
  63. 7.11.2 Wuxi AppTec. Business Overview
  64. 7.11.3 Wuxi AppTec. Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Wuxi AppTec. Oncology Based Preclinical CRO Product Portfolio
  66. 7.11.5 Wuxi AppTec. Recent Developments
  67. 7.12 Xentech
  68. 7.12.1 Xentech Company Information
  69. 7.12.2 Xentech Business Overview
  70. 7.12.3 Xentech Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Xentech Oncology Based Preclinical CRO Product Portfolio
  72. 7.12.5 Xentech Recent Developments
  73. 7.13 Living Tumor Laboratory
  74. 7.13.1 Living Tumor Laboratory Company Information
  75. 7.13.2 Living Tumor Laboratory Business Overview
  76. 7.13.3 Living Tumor Laboratory Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Living Tumor Laboratory Oncology Based Preclinical CRO Product Portfolio
  78. 7.13.5 Living Tumor Laboratory Recent Developments
8 North America
  1. 8.1 North America Oncology Based Preclinical CRO Revenue (2021-2032)
  2. 8.2 North America Oncology Based Preclinical CRO Revenue by Type (2021-2032)
  3. 8.2.1 North America Oncology Based Preclinical CRO Revenue by Type (2021-2026)
  4. 8.2.2 North America Oncology Based Preclinical CRO Revenue by Type (2027-2032)
  5. 8.3 North America Oncology Based Preclinical CRO Revenue Share by Type (2021-2032)
  6. 8.4 North America Oncology Based Preclinical CRO Revenue by Application (2021-2032)
  7. 8.4.1 North America Oncology Based Preclinical CRO Revenue by Application (2021-2026)
  8. 8.4.2 North America Oncology Based Preclinical CRO Revenue by Application (2027-2032)
  9. 8.5 North America Oncology Based Preclinical CRO Revenue Share by Application (2021-2032)
  10. 8.6 North America Oncology Based Preclinical CRO Revenue by Country
  11. 8.6.1 North America Oncology Based Preclinical CRO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Oncology Based Preclinical CRO Revenue by Country (2021-2026)
  13. 8.6.3 North America Oncology Based Preclinical CRO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Oncology Based Preclinical CRO Revenue (2021-2032)
  2. 9.2 Europe Oncology Based Preclinical CRO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Oncology Based Preclinical CRO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Oncology Based Preclinical CRO Revenue by Type (2027-2032)
  5. 9.3 Europe Oncology Based Preclinical CRO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Oncology Based Preclinical CRO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Oncology Based Preclinical CRO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Oncology Based Preclinical CRO Revenue by Application (2027-2032)
  9. 9.5 Europe Oncology Based Preclinical CRO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Oncology Based Preclinical CRO Revenue by Country
  11. 9.6.1 Europe Oncology Based Preclinical CRO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Oncology Based Preclinical CRO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Oncology Based Preclinical CRO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Oncology Based Preclinical CRO Revenue (2021-2032)
  2. 10.2 China Oncology Based Preclinical CRO Revenue by Type (2021-2032)
  3. 10.2.1 China Oncology Based Preclinical CRO Revenue by Type (2021-2026)
  4. 10.2.2 China Oncology Based Preclinical CRO Revenue by Type (2027-2032)
  5. 10.3 China Oncology Based Preclinical CRO Revenue Share by Type (2021-2032)
  6. 10.4 China Oncology Based Preclinical CRO Revenue by Application (2021-2032)
  7. 10.4.1 China Oncology Based Preclinical CRO Revenue by Application (2021-2026)
  8. 10.4.2 China Oncology Based Preclinical CRO Revenue by Application (2027-2032)
  9. 10.5 China Oncology Based Preclinical CRO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oncology Based Preclinical CRO Revenue (2021-2032)
  2. 11.2 Asia Oncology Based Preclinical CRO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Oncology Based Preclinical CRO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Oncology Based Preclinical CRO Revenue by Type (2027-2032)
  5. 11.3 Asia Oncology Based Preclinical CRO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Oncology Based Preclinical CRO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Oncology Based Preclinical CRO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Oncology Based Preclinical CRO Revenue by Application (2027-2032)
  9. 11.5 Asia Oncology Based Preclinical CRO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Oncology Based Preclinical CRO Revenue by Country
  11. 11.6.1 Asia Oncology Based Preclinical CRO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Oncology Based Preclinical CRO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Oncology Based Preclinical CRO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oncology Based Preclinical CRO Revenue (2021-2032)
  2. 12.2 SAMEA Oncology Based Preclinical CRO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Oncology Based Preclinical CRO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Oncology Based Preclinical CRO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Oncology Based Preclinical CRO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Oncology Based Preclinical CRO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Oncology Based Preclinical CRO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Oncology Based Preclinical CRO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Oncology Based Preclinical CRO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Oncology Based Preclinical CRO Revenue by Country
  11. 12.6.1 SAMEA Oncology Based Preclinical CRO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Oncology Based Preclinical CRO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Oncology Based Preclinical CRO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst